Ferrostatin-1 [347174-05-4]
Referência T6500-25mg
Tamanho : 25mg
Marca : TargetMol
Ferrostatin-1
Contact us for more batch information
Purity:99.68%
Resource Download
COA HPLC HNMR
Ferrostatin-1
Catalog No. T6500Cas No. 347174-05-4
Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of iron death. Ferrostatin-1 potently inhibits Erastin-induced iron death in HT-1080 cells with an EC50 of 60 nM. Ferrostatin-1 also exhibits antioxidant and antifungal activities.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. Pack Size | |
---|---|
5 mg | |
10 mg | |
25 mg | |
50 mg | |
200 mg | |
500 mg | |
1 mL x 10 mM (in DMSO) |
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
Description | Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of iron death. Ferrostatin-1 potently inhibits Erastin-induced iron death in HT-1080 cells with an EC50 of 60 nM. Ferrostatin-1 also exhibits antioxidant and antifungal activities. |
In vitro | METHODS: Human bronchial epithelial cells BEAS-2B were co-treated with LPS (10 mg/L) and Ferrostatin-1 (2 μM) for 16 h. The growth inhibition of the cells was detected by CCK-8 method. RESULTS: Ferrostatin-1 attenuated the LPS-induced cell damage. [1] METHODS: Human fibrosarcoma cells HT-1080 were treated with Ferrostatin-1 (0.5 μM) and Erastin (10 μM) for 4 h, and ROS levels produced by the cells were measured by Flow Cytometry. RESULTS: Ferrostatin-1 inhibited the Erastin-induced accumulation of cytoplasmic and lipid ROS. [2] METHODS: Mouse hippocampal neuronal cells HT-22 were treated with Ferrostatin-1 (3-12 μM) for 16 h, then treated with 5 mM glutamate for 24 h, and then LDH release was measured. RESULTS: The release of LDH was significantly increased by treatment with glutamate, and the release of LDH was inhibited by Ferrostatin-1 treatment. [3] |
In vivo | METHODS: To investigate whether iron death is associated with LPS-induced acute kidney injury (AKI), Ferrostatin-1 (5 mg/kg) was administered intraperitoneally in a single dose to C57BL/6 mice, and infectious AKI was induced by intraperitoneal injection of LPS (10 mg/kg) 30 min later. RESULTS: Ferrostatin-1 significantly protected mice from renal dysfunction and tubular injury in LPS-induced AKI. [4] METHODS: To investigate whether iron disorders are associated with acute liver disease and its molecular mechanism, Ferrostatin-1 (2.5 μM/kg) was intraperitoneally injected into ICR mice once a day for three days, followed by intraperitoneal injection of TAA (250 mg/kg/day) for three consecutive days, to establish an acute liver injury (ALI) model in mice. RESULTS: Ferrostatin-1 pretreatment significantly reduced TAA-induced changes in plasma ALT, AST and LDH levels, inhibited the expression of TfR1, Fpn and Ft-L proteins, and decreased iron accumulation without affecting the expression of xCT or GPX4 in the liver. Ferrostatin-1 prevents hepatic iron by decreasing death. [5] |
Cell Research | Cell viability was typically assessed in 384-well format by Alamar Blue fluorescence (ex/em 530/590) measured on a Victor3 plate reader. In some experiments, Trypan Blue dye exclusion counting was performed using an automated cell counter. Cell viability under test conditions is reported as a percentage relative to the negative control treatment [1]. |
Alias | Ferrostatin 1, Ferrostatin-1 (Fer-1) |
Molecular Weight | 262.35 |
Formula | C15H22N2O2 |
Cas No. | 347174-05-4 |
Storage | keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | 5% DMSO+95% Saline: 10 mg/mL (38.12 mM, precipitation) Ethanol: 26.2 mg/mL (100 mM) DMSO: 45 mg/mL (171.53 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/5% DMSO+95% Saline
DMSO
|
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
ROSinhibitFer1cellneurotoxicitycytosolicFerrostatin1FungalantifungalantioxidantFerroptosisFer 1deathInhibitorFer-1Ferrostatin-1